Table 5.
Characteristics and outcomes: comparison between our study and other hip fracture studies
| Our study | Kadowaki | Castronuovo | Kirkland | Maxwell | Roche | |
|---|---|---|---|---|---|---|
| Country, year | US, 2013 | Japan, 2012 | Italy, 2011 | US, 2011 | UK, 2008 | UK, 2005 |
| Total n | 198 | 186 | 6896 | 485 | 4967 | 2448 |
| Study design | Retrospective chart review | Retrospective chart review | Prospective cohort: administrative data registry | Retrospective chart review | Prospective cohort | Prospective observational |
| Mean age (year) SD | 85.9 (5.8) | 84 | n/a | 82.8 (7.8) | 80 | 82 |
| Median age, (range) | 85 (75–104) | (65–105) | 83 (65–106) | 83 (64–106) | (17–102) | (60–103) |
| Female gender, n (%) | 137 (69.19) | 151 (81.2) | 5387 (78) | 356 (73.4) | 76.8% | 1955 (80) |
| 30-day mortality, n (%) | 11 (5.56) | 3 (1.6) | 6.3%a |
53 (10.9) 36 (9.7) over 75 years |
390 (7.9) | 231 (9.6) |
| 90 years or more, n (%) | 54 (27.3) | 50 (26.9) | n/ac | 96 (19.8) | n/a | 465 (19) |
| Type of fracture | ||||||
| Femoral neck | 78 (39.39) | 58 (31) | 6378 (92.5%) | n/a |
4967 (99.9) 0 |
57% Intracapsular, 43% extracapsular |
| Trochanteric | 120 (60.61) | 128 (69) | ||||
| % Conservative | Excluded | Excluded | 16.2% | 7.3% | Excluded | Excludedd |
| Preop risk scoring method | Charlson | ASA | Modified Charlson by Deyo (for ICD9) | Charlson | Nottingham | |
| Patients with 2 or more comorbid conditions, n (%) | 69 (34.85) | 51 (27)b | (9.1) | 56.1% | 1.155 (23.3) | 576 (24) |
n/a data not available
aIncluded patients managed nonoperatively
bSolely corresponds to the amount of patients with 3 or more comorbidities, study does not include amount of patients with only 2 comorbidities
c2,726 (39.5%) greater than 84 years
dExcluded 358 patients including all those aged <60; those with periprosthetic fractures, pathological fractures; fractures treated without surgery; patients who died before surgery